News
RARE
30.77
+5.20%
1.52
Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sander To Board Of Directors
NASDAQ · 3d ago
CALIDI BIOTHERAPEUTICS APPOINTS FORMER GENENTECH/ROCHE AND CELGENE EXECUTIVE CORSEE SANDERS, PH.D., TO BOARD OF DIRECTORS
Reuters · 4d ago
Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs
PUBT · 5d ago
Weekly Report: what happened at RARE last week (0615-0619)?
Weekly Report · 5d ago
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
Seeking Alpha · 6d ago
Ultragenyx grants 44,409 RSUs to 15 new hires under inducement plan
PUBT · 06/19 20:30
ULTRAGENYX REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/19 20:30
Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 06/19 20:30
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
Benzinga · 06/17 17:33
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
Benzinga · 06/17 14:11
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?
Simply Wall St · 06/16 17:37
Ultragenyx Insider Moves: Top Executives Quietly Cash Out in High-Value Stock Sales
TipRanks · 06/16 02:05
Ultragenyx EVP, Chief Legal Officer Karah Parschauer reports sale of 1,899 common shares worth $46,749.38
PUBT · 06/15 22:47
Weekly Report: what happened at RARE last week (0608-0612)?
Weekly Report · 06/15 10:34
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Align Tech (ALGN) and Smith & Nephew Snats (SNN)
TipRanks · 06/10 11:30
Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism
Simply Wall St · 06/09 04:38
Weekly Report: what happened at RARE last week (0601-0605)?
Weekly Report · 06/08 10:29
Does Rising GTX-102 Focus Recast Ultragenyx (RARE) as a Concentrated Angelman Syndrome Risk-Reward Story?
Simply Wall St · 06/06 17:13
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 06/04 18:16
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.